CIK 0001826457
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Monte Rosa Therapeutics, Inc.
Sign in to watch- Ticker
- GLUE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 617-949-2643
- Business address
- 321 HARRISON AVENUE, SUITE 900, BOSTON, MA, 02118
- Former names
- Monte Rosa Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $137
- in 1 filing
Net −$137. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-01 | Behbahani Ali Director | Other disposition | −1,000,000 | 6,692,298 | ||
| 2026-07-01 | Behbahani Ali Director | Other acquisition | +15,000 | 15,000 | ||
| 2026-07-01 | Behbahani Ali Director | Other disposition | −15,000 | 0 | ||
| 2026-06-11 | Behbahani Ali Director | Grant or award · Stock Option (Right to Buy) | +25,800 | 25,800 | ||
| 2025-06-13 | Behbahani Ali Director | Grant or award · Stock Option (Right to Buy) | +30,700 | 30,700 | ||
| 2024-06-12 | Behbahani Ali Director | Grant or award · Stock Option (Right to Buy) | +22,100 | 22,100 | ||
| 2023-06-14 | Behbahani Ali Director | Grant or award · Stock Option (Right to Buy) | +20,500 | 20,500 | ||
| 2022-06-15 | Behbahani Ali Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2021-06-28 | Behbahani Ali Director | Conversion | +2,715,968 | 2,715,968 | ||
| 2021-06-28 | Behbahani Ali Director | Conversion | +3,257,328 | 5,973,296 | ||
| 2021-06-28 | Behbahani Ali Director | Conversion | +669,002 | 6,642,298 | ||
| 2021-06-28 | Behbahani Ali Director | Purchase | +1,050,000 | $19.00 | $19.9M | 7,692,298 |
| 2021-06-28 | Behbahani Ali Director | Conversion · Series A-2 convertible preferred stock | −9,588,725 | 0 | ||
| 2021-06-28 | Behbahani Ali Director | Conversion · Series B convertible preferred stock | −11,500,000 | 0 | ||
| 2021-06-28 | Behbahani Ali Director | Conversion · Series C convertible preferred Stock | −2,361,912 | 0 | ||
| 2021-06-23 | Behbahani Ali Director | Grant or award · Stock Option (Right to Buy) | +47,132 | 47,132 |
Page 1 of 1 · 16 trades